Benchmark Share Discussion Threads

[exbroker] 21/11/2014 18:57

If you have not seen it look at the RNS from Friday night.


This is a good deal, they have come from nowhere to be the second biggest salmon egg producer. The biggest is so upset that they tried to derail it by buying stock in Stofnfiskur hence the minorities in the pro forma numbers.
I met the management 10 days ago and have taken stock in the placing which was oversubscribed and has a number of new high quality shareholders on the list.
It all ties in well with what they are trying to build long term and that's a world class aquaculture business.

From the FT

[hydrus] 21/11/2014 18:54

Well that RNS is a lot to take in, where to start! The acquisitions seem to be fairly expensive.

[gucci] 19/11/2014 14:08

time for this to start moving up soon

[lozler] 06/11/2014 20:40

If I'm not mistaken, it's benchmarks end of year this month, so a report / update should be due end of the month, or start of next.

[gucci] 06/11/2014 18:45

good trades today
hope it continues

[protean] 06/11/2014 11:27

Someone has been accumulating in 25k blocks by the looks of it.

Certainly more buying interest coming in again.

SCSW recommendation in Sept was:

"At some point in the not too distant future, these shares are set to catch fire. Buy for that."

[gucci] 06/11/2014 08:55

starting to move up

[nw99] 01/10/2014 17:39

Sellers came back in shame

[montynj] 01/10/2014 15:46

Now that it has broken out of that consolidation pattern use all bouts of intra day weakness to buy

[dlku] 01/10/2014 14:10

may get to 140p Slater likes it also

[nw99] 01/10/2014 12:54

Indeed its a buy here

[protean] 01/10/2014 12:50

Large volume the other day was most likely the overhang (which had been holding price back) clearing.

SCSW very keen on the shares. Sept edition concludes: "At some point in the not too distant future, these shares are set to catch fire. Buy for that."

[montynj] 01/10/2014 12:37

I agree...finally uptrend started

[dlku] 01/10/2014 12:32

SOMETHING HAPPENING

[nw99] 01/10/2014 12:22

Looks to have bottomed chart breakout

[lozler] 30/9/2014 22:47

Nice rise today, wonder if there's something brewing

[thorne3] 23/9/2014 09:55

For the time being the share price is clearly being managed at 85p on the offer side.A number of institutions who bought in at the original placement price of 64p are gradually taking a modicum of profit;nothing wrong there.In due course this selling will be absorbed as the potentially exciting newsflow unfolds.At that stage the share price could move quite materially as the market as a whole begins to appreciate the attractions and very considerable potential of this amazing company.

[lozler] 22/9/2014 17:29

It's only a matter of time the MM's lift the lid on this one, have a look at the considerable amount of buys on the ASK from last week to now, all on 85p.

[dlku] 22/9/2014 16:02

went shooting up on Friday wonder if we will get the same at the close. Big buying was seen then

[nw99] 22/9/2014 11:56

I cannot make it but NMJ as shareholder will go as my replacement

[opodio] 22/9/2014 11:34

freeing up cash to buy some more on next move up

[montynj] 22/9/2014 10:44

nw99 looks like he will be going to meeting on 25th so he'll report back to the rest of us

[opodio] 22/9/2014 09:44

BMK: The vaccine jab for kitty that could cure your allergy to cats:


Millions of cat allergy sufferers know the symptoms only too well – red, itchy eyes, uncontrollable sneezes, coughing fits, even a nasty rash.
But help could soon be at hand thanks to a British company working on a vaccine it says can render even the fluffiest feline totally harmless.
Sheffield-based Benchmark says its revolutionary injection can ‘neutralise’ the cat itself, rather than forcing humans to resort to costly treatments that often have limited effect.
A British company is working on a vaccine which it says can render even the fluffiest feline totally harmless to allergy sufferers
+2
A British company is working on a vaccine which it says can render even the fluffiest feline totally harmless to allergy sufferers
It works by attacking a protein carried in cats’ saliva, urine and sweat that is the most common cause of cat allergies.
More than 725m people, about a tenth of the global population, are thought to be allergic to cats but options for alleviating the symptoms are limited.



Sufferers can take anti-histamines or have regular injections designed to stimulate the body’s natural immune system.
Some websites recommend using air purifiers or even bathing your cat as often as possible, which can prove difficult if the animal doesn’t cooperate.
The new vaccine, dubbed HypoCat, works by attacking the Fel d 1 protein, the main allergen carried by cats and kittens.
Fel d 1, present in saliva, urine and sweat, is spread all over the cat’s fur when it licks itself clean.
Pugh Allergy Job.jpg
+2
The protein then attaches itself to cat dander, tiny particles of dry skin one tenth the size of a dust mite.
As cats prowl their territory, they leave dander on surfaces such as bedding and sofas, wreaking havoc on allergy sufferers whose symptoms are triggered by the protein.
But Benchmark claims that HypoCat can ‘neutralise’ the Fel d 1 protein altogether, without harming the cat.
It is spending up to £8million to commercialise research by Swiss firm HypoPet, based at the University of Zurich, in the hope of making HypoCat available through vets within three or four years.
Maureen Jenkins, clinical director of Allergy UK, said the vaccine could make a huge difference to allergy suffereds in the UK, which hosts an army of around 8.5million cats.
‘It’s a major problem in this country so this could be very significant,’ she said.
‘Some people avoid cats like the plague and when they are then exposed they could have a very serious reaction.’
‘It’s also something that can cause chronic ongoing systems and a lot of people don’t realise what the cause is.’
Benchmark said it believes that HypoCat could open up a new market for cat vaccinations worth as much as £250million.
Life sciences analysts at City of London firm Cenkos Securities said: ‘There is a large potential market for this vaccine.’
‘We believe that this approach will lead to a relatively straightforward solution for cat owners and the population that suffers from cat allergies,’ they added.



Read more: